Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 20/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 0.66 |
| ▸ | CHUK | O15111 | 1/20 | 0.66 |
| ▸ | AKT1 | P31749 | 1/20 | 0.66 |
| ▸ | AKT2 | P31751 | 1/20 | 0.66 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.66 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612171 | 1.00 | PADI4 (1.00) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL23468130 | 0.91 | PADI4 (0.84) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL23468060 | 0.89 | PADI4 (1.00) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL23468068 | 0.89 | PADI4 (1.00) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL23467955 | 0.87 | PADI4 (1.00) | PADI4 | |
| SCHEMBL30044239 | 0.87 | PADI4 (1.00) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL19863741 | 0.87 | PADI4 (1.00) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL23497993 | 0.87 | PADI4 (1.00) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL23468065 | 0.85 | PADI4 (0.74) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL19863736 | 0.84 | PADI4 (0.86) | PADI4IKBKBCHUKAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510025-B1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3510025-B1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-110248934-B | Heteroaryl PAD4 inhibitors | 帕德罗科治疗公司 | 2022-05-24 | — | — | CN | disclosed |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-09-30 | — | — | US | disclosed |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3510025-A1 | HETEROARYL INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018049296-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | PADI4 1/4885IKBKB 1218/4885CHUK 923/4885 |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | PADI4 1/4885IKBKB 1218/4885CHUK 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.